LeMaitre Vascular (NASDAQ: LMAT) is one of 83 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare LeMaitre Vascular to similar businesses based on the strength of its earnings, institutional ownership, profitability, risk, analyst recommendations, dividends and valuation.

Volatility and Risk

LeMaitre Vascular has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, LeMaitre Vascular’s rivals have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Insider & Institutional Ownership

68.3% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 23.7% of LeMaitre Vascular shares are held by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares LeMaitre Vascular and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LeMaitre Vascular 15.81% 16.16% 14.03%
LeMaitre Vascular Competitors -327.74% -35.51% -12.38%

Dividends

LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.7%. LeMaitre Vascular pays out 28.6% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.0% of their earnings in the form of a dividend. LeMaitre Vascular lags its rivals as a dividend stock, given its lower dividend yield and higher payout ratio.

Analyst Recommendations

This is a summary of current ratings and recommmendations for LeMaitre Vascular and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LeMaitre Vascular 0 5 1 0 2.17
LeMaitre Vascular Competitors 266 1847 3304 105 2.59

LeMaitre Vascular currently has a consensus target price of $31.50, suggesting a potential upside of 1.96%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.04%. Given LeMaitre Vascular’s higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than its rivals.

Earnings and Valuation

This table compares LeMaitre Vascular and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
LeMaitre Vascular $96.40 million $23.12 million 40.12
LeMaitre Vascular Competitors $2.06 billion $438.96 million -75.61

LeMaitre Vascular’s rivals have higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

LeMaitre Vascular rivals beat LeMaitre Vascular on 8 of the 15 factors compared.

About LeMaitre Vascular

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.